莱纳巴苏姆是一种大麻素2型受体激动剂,在皮肤肌炎中具有抗炎作用
DeAnna Diaz1, Thomas Vazquez1, Nilesh Kodali1
1Corporal Michael J. Crescenz VAMC, Philadelphia, PA; Department of Dermatology, Perelman School of Medicine, University of Pennsylvania.
The Journal of investigative dermatology
|January 16, 2026
概括
莱纳巴,一种大麻素受体2型 (CB2) 激动剂,通过向免疫细胞来减少皮肤肌炎 (DM) 中的炎症性细胞因子. 这可能解释了它在DM皮肤炎症中的有效性.
科学领域:
- 免疫学 免疫学 免疫学
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 皮肤肌肉炎 (DM) 是一种致残的自身免疫性疾病,治疗选择有限.
- 目前用于DM的治疗方法在约一半的患者中是无效的,这凸显了对新型治疗方法的需求.
- 莱纳巴是一种选择性大麻素受体2型 (CB2) 激动剂,提供一种非免疫抑制方法来调节免疫反应.
研究的目的:
- 研究Lenabasum对皮肤肌肉炎 (DM) 皮肤和外周血液单核细胞 (PBMC) 免疫细胞的抗炎作用.
- 分析Lenabasum对特定炎症和促进的细胞因子的影响,例如IL-31.
- 探索CB2受体表达在调解Lenabasum在DM治疗潜力的作用.
主要方法:
- 对DM皮肤和PBMCs的多重化细胞因子分析.
- 评估Lenabasum对CD4+T细胞,Th1细胞和单细胞衍生的树突细胞 (moDC) 的影响.
- 试验CB2受体的淘汰,以确认它的作用机制.
主要成果:
- 莱纳巴显示出显著的抗炎作用,特别是在CD4+T细胞,Th1细胞和髓状细胞系上.
- 抑制Th1衍生的和moDC衍生的IL-31,这是DM相关的的关键细胞因子.
- 抑制CB2受体取消了Lenabasum的抗炎作用,证实了它的作用机制.
- 与PBMC相比,DM皮肤细胞中较高的CB2表达和反应表明局部治疗效果.
结论:
- 莱纳巴通过CB2受体激活,有效地降低了包括IL-31在内的促炎细胞因子的下调.
- 药物对透到皮肤的免疫细胞的强效作用可能解释了其在DM皮肤表现中的观察到的有效性.
- 莱纳巴桑代表了皮肤肌炎的有希望的治疗候选者,特别是用于管理与皮肤有关的症状.
相关概念视频
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
499
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
499
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
493
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
493
01:19Antiasthma Drugs: Leukotriene Modifiers
1.8K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.8K
01:29Inflammatory Bowel Disease IV: Pharmacological Management
528
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
528
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
439
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
439
01:29Drugs for Treatment of Ulcerative Colitis in IBD
463
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
463